Abstract
There is an increasing need for successfully managing the rapidly progressing posterior eye diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma. Therefore the challenges of drug delivery to the posterior eye are compounded by growing number of new therapeutic entities and the need for chronic therapy. Currently, the intravitreal route is widely used to deliver drugs, but frequent administration of drugs via this route can lead to retinal detachment, endophthalmitis and increased intraocular pressure. Controlled delivery systems, such as implants and nanoparticles have been developed to overcome these issues, but they are not devoid of adverse effects. Periocular route is a promising alternative owing to the large surface area and the relatively high permeability of the sclera. Yet, the blood retinal barriers and efflux transporters hamper the transport of therapeutic entities to the retina. As such the efficient delivery of drugs to the posterior eye remains a major challenge facing the pharmaceutical scientist. This review discusses the barriers to posterior eye drug delivery and current strategies used to overcome these barriers.
Keywords: Implants, Intravitreal route, Iontophoresis, Microneedles, Posterior eye drug delivery, Transscleral route, Drug Delivery Systems, transscleral routes, transdermal delivery
Drug Delivery Letters
Title: Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities
Volume: 1 Issue: 1
Author(s): T. R. Thrimawithana, S. Young, C. R. Bunt, C. R. Green and R. G. Alany
Affiliation:
Keywords: Implants, Intravitreal route, Iontophoresis, Microneedles, Posterior eye drug delivery, Transscleral route, Drug Delivery Systems, transscleral routes, transdermal delivery
Abstract: There is an increasing need for successfully managing the rapidly progressing posterior eye diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma. Therefore the challenges of drug delivery to the posterior eye are compounded by growing number of new therapeutic entities and the need for chronic therapy. Currently, the intravitreal route is widely used to deliver drugs, but frequent administration of drugs via this route can lead to retinal detachment, endophthalmitis and increased intraocular pressure. Controlled delivery systems, such as implants and nanoparticles have been developed to overcome these issues, but they are not devoid of adverse effects. Periocular route is a promising alternative owing to the large surface area and the relatively high permeability of the sclera. Yet, the blood retinal barriers and efflux transporters hamper the transport of therapeutic entities to the retina. As such the efficient delivery of drugs to the posterior eye remains a major challenge facing the pharmaceutical scientist. This review discusses the barriers to posterior eye drug delivery and current strategies used to overcome these barriers.
Export Options
About this article
Cite this article as:
R. Thrimawithana T., Young S., R. Bunt C., R. Green C. and G. Alany R., Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities, Drug Delivery Letters 2011; 1(1) . https://dx.doi.org/10.2174/2210304x11101010040
DOI https://dx.doi.org/10.2174/2210304x11101010040 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke
Current Neurovascular Research VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research Current Management of Extracranial Carotid Artery Disease
Reviews on Recent Clinical Trials Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Novel Vitreous Modulators for Pharmacologic Vitreolysis in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets